Article

Vial launches VialConnect: Modernized CTMS with patient recruitment assistance

The company's VialConnect is an intuitive clinical trials management platform built for coordinators and investigators.

Vial this week announced the debut of VialConnect, an intuitive clinical trials management platform built for coordinators and investigators.

According to the company, VialConnect is offered at no cost and makes it simple for research sites to access Vial’s modernized CTMS and additional services for patient recruitment.

The company noted in a news release that signing up for VialConnect gives sites access to 2 services for free: First, a customizable CTMS (clinical trials management system) that powers core workflows and provides operational visibility. And second, A HIPAA-compliant EMR filtering tool making it easier to sort potential trial subjects.

"Since implementing Vial's CTMS at our sites, our team's day-to-day operations have become faster and more efficient,” Stacey Gomez, a clinical research manager and one of the first users said in a statement. “We can easily schedule new appointments, track patients, and view all of our studies in one place. It's easy to navigate and our team loves it.”

Simon Burns, co-founder and CEO of Vial, noted that the company talked extensively with PIs and CRCs to identify their main pain points — the lack of an intuitive CTMS and an inability to recruit patients efficiently.

VialConnect solves these issues through modernized tech solutions,” he said in the release. “After deploying VialConnect at our 30+ partner sites, it’s clear from their feedback that our CTMS and patient recruitment program wins in all of these areas.”

Vial strives to be a next generation site management organization by providing the necessary resources for research practices to run trials with faster execution and higher quality.

The company has over 90 employees and is based in San Francisco, California.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
© 2025 MJH Life Sciences

All rights reserved.
OSZAR »